Biotech Values

[dav1234]

Judge affirms patent on Eli Lilly lung-cancer drug
A district judge has upheld the validity of a patent on Eli Lilly's (LLY) blockbuster Alimta lung-cancer drug, which generates sales of $2.6B a year.
The decision will maintain the treatment's exclusivity until 2022, pending the outcome of any appeal.
Companies on the losing side in the case include Teva (TEVA) and Fresenius Kabi (APCVZ).
http://seekingalpha.com/pr/9427913-u-s-district-court-upholds-validity-of-lillys-alimta-patent-through-2022